Provide feedbackProvide feedback

Home :: Psychiatry :: Psychiatry Conferences :: U.S. Psychiatric & Mental Health Congress 2007

U.S. Psychiatric & Mental Health Congress

U.S. Psychiatric & Mental Health Congress 2007

October 11-14, 2007Orlando, FL
VerusMed is an independent news organization and is not affiliated with the U.S. Psychiatric & Mental Health Congress

Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events

Wednesday, December 12, 2007 | Comments

The methylphenidate transdermal system (MTS) appears to be similarly effective in male and female children with attention-deficit/hyperactivity disorder, although males may face a higher incidence of adverse events, study data indicate.

Researchers conducted a double-blind, placebo-controlled, parallel-group study in ...[more] Locked

Comorbidities extremely common in children with ADHD; effective patient management requires treating these illnesses as well, experts report

Wednesday, December 12, 2007 | Comments

Comorbidities may be present in as many as two-thirds of children with attention-deficit/hyperactivity disorder, and treating these comorbidities should be considered an integral part of effectively managing these children, a pair of experts in the field indicated.

"Psychiatric comorbidity [in children with ADHD] is ...[more] Locked

OROS methylphenidate safe, effective in adults with ADHD, trial data show

Wednesday, December 12, 2007 | Comments

OROS methylphenidate appears safe and effective in adults with attention-deficit/hyperactivity disorder, eliciting dose-dependent improvements in inattention and hyperactivity/impulsivity symptoms, according to findings from the double-blind LAMDA trial.

Researchers randomized 401 adult patients with ADHD and a ...[more] Locked

Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events

Wednesday, December 12, 2007 | Comments

The methylphenidate transdermal system (MTS) appears to be similarly effective in male and female children with attention-deficit/hyperactivity disorder, although males may face a higher incidence of adverse events, study data indicate.

Researchers conducted a double-blind, placebo-controlled, parallel-group study in ...[more] Locked

Comorbidities extremely common in children with ADHD; effective patient management requires treating these illnesses as well, experts report

Wednesday, December 12, 2007 | Comments

Comorbidities may be present in as many as two-thirds of children with attention-deficit/hyperactivity disorder, and treating these comorbidities should be considered an integral part of effectively managing these children, a pair of experts in the field indicated.

"Psychiatric comorbidity [in children with ADHD] is ...[more] Locked

OROS methylphenidate safe, effective in adults with ADHD, trial data show

Wednesday, December 12, 2007 | Comments

OROS methylphenidate appears safe and effective in adults with attention-deficit/hyperactivity disorder, eliciting dose-dependent improvements in inattention and hyperactivity/impulsivity symptoms, according to findings from the double-blind LAMDA trial.

Researchers randomized 401 adult patients with ADHD and a ...[more] Locked

Guanfacine XR effective, safe in treating ADHD in children, adolescents, researchers report

Wednesday, December 12, 2007 | Comments

Guanfacine extended release (XR) appears effective in treating children and adolescents with attention-deficit/hyperactivity disorder, according to data from a short-term study.

"Many individuals with ADHD do not respond to, cannot tolerate, or prefer alternatives to stimulant treatment," the authors of the study ...[more] Locked

Abuse potential with OROS methylphenidate lower than with other methylphenidate formulations

Wednesday, December 12, 2007 | Comments

The number of emergency department (ED) reports of abuse with OROS methylphenidate appears to be lower than the number of reports for other formulations of methylphenidate, based on a recent analysis.

Researchers evaluated data from the Drug Abuse Warning Network (DAWN), which is a ...[more] Locked

AISRS useful in measuring methylphenidate therapy for adults with ADHD

Wednesday, December 12, 2007 | Comments

The Adult Attention-Deficit/Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) is a sensitive instrument that measures the effect of methylphenidate treatment on the signs and symptoms of ADHD among adults, new data reveal.

The AISRS is a modified version of the ADHD Rating Scale that more accurately ...[more] Locked

Lisdexamfetamine improves parent-rated measures of ADHD

Wednesday, December 12, 2007 | Comments

Treatment with lisdexamfetamine dimesylate appears to significantly improve parent-rated measures of attention-deficit/hyperactivity disorder in children relative to placebo, a post hoc analysis shows.

The secondary analysis was based on data from a double-blind, Phase III trial in which 290 children aged 6 to 12 years ...[more] Locked

Abuse potential with OROS methylphenidate lower than with other methylphenidate formulations

Wednesday, December 12, 2007 | Comments

The number of emergency department (ED) reports of abuse with OROS methylphenidate appears to be lower than the number of reports for other formulations of methylphenidate, based on a recent analysis.

Researchers evaluated data from the Drug Abuse Warning Network (DAWN), which is a ...[more] Locked

AISRS useful in measuring methylphenidate therapy for adults with ADHD

Wednesday, December 12, 2007 | Comments

The Adult Attention-Deficit/Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) is a sensitive instrument that measures the effect of methylphenidate treatment on the signs and symptoms of ADHD among adults, new data reveal.

The AISRS is a modified version of the ADHD Rating Scale that more accurately ...[more] Locked

Guanfacine XR effective, safe in treating ADHD in children, adolescents, researchers report

Wednesday, December 12, 2007 | Comments

Guanfacine extended release (XR) appears effective in treating children and adolescents with attention-deficit/hyperactivity disorder, according to data from a short-term study.

"Many individuals with ADHD do not respond to, cannot tolerate, or prefer alternatives to stimulant treatment," the authors of the study ...[more] Locked

Lisdexamfetamine improves parent-rated measures of ADHD

Wednesday, December 12, 2007 | Comments

Treatment with lisdexamfetamine dimesylate appears to significantly improve parent-rated measures of attention-deficit/hyperactivity disorder in children relative to placebo, a post hoc analysis shows.

The secondary analysis was based on data from a double-blind, Phase III trial in which 290 children aged 6 to 12 years ...[more] Locked

Once identified, adult ADHD may be managed effectively with drugs, psychosocial therapy, experts suggest

Wednesday, December 12, 2007 | Comments

Identifying adults with attention-deficit/hyperactivity disorder can be difficult, largely due to popular misconceptions about the illness, but once diagnosed, ADHD can be effectively managed with pharmacologic and nonpharmacologic therapy, according to a pair of experts in the field.

Many adults with ADHD may be ...[more] Locked

Stimulant dosing in adults with ADHD lower than effective levels

Wednesday, December 12, 2007 | Comments

Dosing of stimulants for adults with attention-deficit/hyperactivity disorder appears to fall well below dose ranges that have been shown to be optimally effective in trials of adults with ADHD, according to a new study.

Researchers used service and pharmacy claims from the ...[more] Locked

Methylphenidate transdermal system linked to deficits in expected growth in children with ADHD

Wednesday, December 12, 2007 | Comments

Treatment with the methylphenidate transdermal system (MTS) is associated with small deficits in expected height, weight, and body mass index among children with attention-deficit/hyperactivity disorder; however, new data suggest that these deficits appear to attenuate during time.

"Although stimulant treatment is highly ...[more] Locked

Guanfacine XR effective, safe in long-term treatment of ADHD

Wednesday, December 12, 2007 | Comments

Guanfacine extended release (XR) appears to be a safe and effective treatment option for the long-term management of attention-deficit/hyperactivity disorder among children and adolescents, new data show.

Researchers performed an open-label, extension study of up to 24 months. Participants were children aged 6 to 17 years ...[more] Locked

Once identified, adult ADHD may be managed effectively with drugs, psychosocial therapy, experts suggest

Wednesday, December 12, 2007 | Comments

Identifying adults with attention-deficit/hyperactivity disorder can be difficult, largely due to popular misconceptions about the illness, but once diagnosed, ADHD can be effectively managed with pharmacologic and nonpharmacologic therapy, according to a pair of experts in the field.

Many adults with ADHD may be ...[more] Locked

Stimulant dosing in adults with ADHD lower than effective levels

Wednesday, December 12, 2007 | Comments

Dosing of stimulants for adults with attention-deficit/hyperactivity disorder appears to fall well below dose ranges that have been shown to be optimally effective in trials of adults with ADHD, according to a new study.

Researchers used service and pharmacy claims from the ...[more] Locked

Guanfacine XR effective, safe in long-term treatment of ADHD

Wednesday, December 12, 2007 | Comments

Guanfacine extended release (XR) appears to be a safe and effective treatment option for the long-term management of attention-deficit/hyperactivity disorder among children and adolescents, new data show.

Researchers performed an open-label, extension study of up to 24 months. Participants were children aged 6 to 17 years ...[more] Locked

Methylphenidate transdermal system linked to deficits in expected growth in children with ADHD

Wednesday, December 12, 2007 | Comments

Treatment with the methylphenidate transdermal system (MTS) is associated with small deficits in expected height, weight, and body mass index among children with attention-deficit/hyperactivity disorder; however, new data suggest that these deficits appear to attenuate during time.

"Although stimulant treatment is highly ...[more] Locked



  1. No articles have been read
  1. No articles have been emailed
Videos